(Q37708567)

22 August 2017

1 reference

title

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities (English)

1 reference

Japanese encephalitis virus

22 August 2017

0 references

1 reference

1 reference

Japanese encephalitis

1 reference

1 reference

Yongxin Yu

1

1 reference

PubMed ID

20226891

22 August 2017

language of work or name

English

0 references

publication date

11 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

21

1 reference

22 August 2017

3635-3641

1 reference

Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.105

10.1016/J.VACCINE.2010.02.105

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20226891